Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,680 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study.
Yana T, Negoro S, Takada M, Yokota S, Takada Y, Sugiura T, Yamamoto H, Sawa T, Kawahara M, Katakami N, Ariyoshi Y, Fukuoka M; West Japan Thoracic Oncology Group. Yana T, et al. Among authors: yokota s. Invest New Drugs. 2007 Jun;25(3):253-8. doi: 10.1007/s10637-006-9012-9. Epub 2006 Oct 13. Invest New Drugs. 2007. PMID: 17039404 Clinical Trial.
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.
Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N. Takada M, et al. Among authors: yokota s. J Clin Oncol. 2002 Jul 15;20(14):3054-60. doi: 10.1200/JCO.2002.12.071. J Clin Oncol. 2002. PMID: 12118018 Clinical Trial.
Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.
Sawa T, Yana T, Takada M, Sugiura T, Kudoh S, Kamei T, Isobe T, Yamamoto H, Yokota S, Katakami N, Tohda Y, Kawakami A, Nakanishi Y, Ariyoshi Y. Sawa T, et al. Among authors: yokota s. Invest New Drugs. 2006 Mar;24(2):151-8. doi: 10.1007/s10637-006-5937-2. Invest New Drugs. 2006. PMID: 16502350 Clinical Trial.
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M. Yamamoto N, et al. Among authors: yokota s. J Clin Oncol. 2010 Aug 10;28(23):3739-45. doi: 10.1200/JCO.2009.24.5050. Epub 2010 Jul 12. J Clin Oncol. 2010. PMID: 20625120 Clinical Trial.
Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H; Japanese Taxotere Lung Cancer Study Group. Kubota K, et al. Among authors: yokota s. J Clin Oncol. 2004 Jan 15;22(2):254-61. doi: 10.1200/JCO.2004.06.114. J Clin Oncol. 2004. PMID: 14722033 Clinical Trial.
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.
Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M; JO19907 Study Group. Niho S, et al. Among authors: yokota s. Lung Cancer. 2012 Jun;76(3):362-7. doi: 10.1016/j.lungcan.2011.12.005. Epub 2012 Jan 14. Lung Cancer. 2012. PMID: 22244743 Free article. Clinical Trial.
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S. Otsuka T, et al. Among authors: yokota s. Anticancer Res. 2015 Jul;35(7):3885-91. Anticancer Res. 2015. PMID: 26124334
Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
Hata A, Katakami N, Hattori Y, Tanaka K, Fujita S, Kotani Y, Nishimura T, Imamura F, Yokota S, Satouchi M, Monden K, Otsuka K, Nishiyama A, Tsubouchi K, Kaneda T, Yoshioka H, Morita S, Negoro S. Hata A, et al. Among authors: yokota s. Cancer Chemother Pharmacol. 2017 Apr;79(4):689-695. doi: 10.1007/s00280-017-3259-z. Epub 2017 Mar 9. Cancer Chemother Pharmacol. 2017. PMID: 28280972 Clinical Trial.
1,680 results